Results 101 to 110 of about 2,191 (125)

Metastatic Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2B (MEN 2B) With RET M918T Mutation: Challenges in Long-Term Management and Targeted Therapy. [PDF]

Cureus
Rahman Z, Clark B, Ali K, Choudhry H, Weimer L, Parza K, Bastidas Mora G.   +6 more
europepmc   +1 more source

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. [PDF]

Drugs Context
Karapanou O, Effraimidis G, Michalaki M, Saltiki K.   +3 more
europepmc   +1 more source

Loss of WT1 Drives Adaptive Plasticity in CCDC6-RET Selpercatinib-Resistant Papillary Thyroid Cancer. [PDF]

Curr Issues Mol Biol
Siragusa G, Tomasello L, Biondo M, Vaglica F, Giordano C, Arnaldi G, Pizzolanti G.   +6 more
europepmc   +1 more source

Erratum to Acute β-cell failure induced by selpercatinib in RET fusion-positive non-small cell lung cancer: A case report [Respir. Med. Case Rep. 59 (2026) 102372]. [PDF]

Respir Med Case Rep
Tsukao H, Kojima R, Nakanishi S, Miyanishi Y, Fujii Y, Yamaguchi W, Nakaya J, Kojima T.   +7 more
europepmc   +1 more source

Molecular and Clinical Profile of a RET-Rearranged Colorectal Cancer With Prolonged Response to Platinum Therapy and Subsequent Targeted Treatment With Selpercatinib. [PDF]

JCO Precis Oncol
Trovato G, Basso M, De Rose AM, Giuliante F, Alfieri S, Minucci A, Nardi E, Arena V, Salvatore L, Tortora G, Calegari MA.   +10 more
europepmc   +1 more source

Acute β-cell failure induced by selpercatinib in RET fusion-positive non-small cell lung cancer: A case report. [PDF]

Respir Med Case Rep
Tsukao H, Kojima R, Nakanishi S, Miyanishi Y, Fujii Y, Yamaguchi W, Nakaya J, Kojima T.   +7 more
europepmc   +1 more source

Selpercatinib-induced Acalculous Cholecystitis in an Elderly Patient with RET Fusion-positive Non-small Cell Lung Cancer. [PDF]

Intern Med
Ichikawa T, Sato K, Sasano Y, Matsumoto S, Matsuoka S, Takigawa Y, Watanabe H, Kudo K, Sato A, Fujiwara K, Shibayama T.   +10 more
europepmc   +1 more source

Two Cases of Papillary Thyroid Carcinoma With QTc Prolongation During Selpercatinib Administration: A Case Report. [PDF]

Cureus
Nanjo K, Kida W, Mori A, Inayoshi Y, Nakaya M.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

Annals of Oncology, 2021
Blaine Mooers, Jie Wu, Vivek Subbiah
exaly